Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Secondary hyperlipoproteinemias are found in connection with other primary organic diseases. Typical examples are those seen with diabetes mellitus, liver and kidney diseases. In addition there are changes induced by hormonal dysfunctions such as hypothyroidism, by the use of oral contraceptives or in postmenopausal women. During pregnancy there is a physiological transient increase in lipoproteins. In addition to primary organic diseases there are a number of exogenous factors such as obesity, malnutrition and alcohol abuse causing hyperlipidemia. The relation between hypertension and hyperlipidemia described as familial dyslipidemic hypertension is less well known. Obesity, hypertension, dyslipidemia, hyperuricemia and impaired glucose tolerance are the basic conditions of the metabolic syndrome. Familial combined hyperlipidemia is a genetically determined, dyslipidemic syndrome with a high prevalence among patients with coronary artery disease and stroke. As there are some links between familial combined hyperlipidemia and secondary hyperlipoproteinemias, this disease entity is discussed together in this paper. Familial combined hyperlipidemia is metabolically, genetically and by this on a molecular level closely linked to familial dyslipidemic hypertension as well as the metabolic syndrome. The exact mechanism of this disease is currently unknown.
 ...
PMID:[Secondary disorders of lipid metabolism, metabolic syndrome and familial combined hyperlipidemia]. 865 Sep 33

Important observations have continued to expand our understanding of gout. The increased risk of gout in black Americans has been linked more closely with the development of hypertension, and an increasing prevalence in African blacks and in England may have a similar association, possibly through the use of diuretics. The association of gout and insulin resistance appears to be related to fat distribution, and the link with hyperlipidemia may be related to genetic factors. The relationship between gout and renal disease and the frequency of gout in patients with renal failure continue to be areas of controversy. The mechanism and a possible therapeutic approach to the hyperuricemia associated with cyclosporine therapy are better understood. The potential for antibodies against urate crystals to potentiate further crystallization may explain some of the uncertainties about gouty attacks. Unusual manifestations of gout, including more cases of spinal involvement, were reported. The role of formalin in dissolving urate crystals in pathologic specimens was further clarified, and the use of atomic force microscopy to detect crystals was reported. Corticosteroids are increasingly accepted in treating acute gout, and the role of colchicine in acute and intercritical gout has come under increasing scrutiny. Urate-lowering drugs appear to be cost effective in patients with more than one or two attacks per year.
 ...
PMID:Gouty arthritis and uric acid metabolism. 879 84

The study purpose was to determine the following in a large sample of hospitalized patients: (1) the prevalence of hyperuricemia, (2) the association of hyperuricemia with other metabolic disorders, and (3) the factors independently predicting hyperuricemia. Five hundred adult patients (250 men and 250 women) were randomly selected from those admitted as inpatients over a period of 5 months. In all patients, body mass index (BMI), blood pressure, and serum glucose, lipid, creatinine, urea nitrogen, and urate concentrations were measured. The presence of diseases or use of medications known to affect serum urate levels were recorded. The mean level of serum urate was 5.6 mg/dL in the whole sample, 6.0 mg/dL in men and 5.3 mg/dL in women (P = .003, men v women). The prevalence of hyperuricemia was 27.6% (28.8% and 26.4% in men v women, P = nonsignificant). A definite or probable secondary hyperuricemia was found in 87.7% of the subjects. Hyperuricemia was rarely isolated (21%), whereas it was frequently associated with hypertension (60.1%), hyperlipidemia (31.2%), diabetes (28.3%), and obesity (21.7%). In 26.8% of the subjects, hyperuricemia was associated with two metabolic disorders, in 13.8% with three, and in 2.9% with four. Multiple metabolic disorders (three to four) were found in 16.7% of subjects with hyperuricemia. Serum urate levels progressively increased across a range of subjects from those without diabetes, hyperlipidemia, hypertension, or obesity to those with one, two, or a greater number of associated metabolic abnormalities. Multiple stepwise regression analysis showed that 43% of serum urate variability was explained by urea nitrogen levels, triglyceride levels, diuretic therapy, the inverse of creatinine (as an index linearly related to creatinine clearance), and BMI. These results indicate that in hospitalized subjects, hyperuricemia is (1) frequent, (2) a secondary phenomenon in most cases, and (3) frequently associated with other metabolic disorders. The major predictors of high serum urate levels are BMI, triglycerides, parameters of renal function, and use of diuretics. These variables explain a large proportion of serum urate variability.
 ...
PMID:Serum uric acid and related factors in 500 hospitalized subjects. 896 92

Characteristic feature of pathogenesis, epidemiology and laboratory findings in hyperuricemia of gouty patients are studied and reasonable treatments of gout in clinical medicine are discussed. Gout is characterized by repeated arthritis attacks on the metacarpophalangeal joint of the first toe or other small joints, especially overworked joints or those exposed to cold. The arthritis attack lasts for 3.5 days and then diminishes gradually. The intervals are shortened in patients under poor hyperuricemic control but tophi formation is less frequent. Complications in combination with hyperlipidemia, diabetes mellitus, obesity and hypertension, which are compatible to syndrome X, are frequent in gouty patients and are suspected of rapidly progressing to arteriosclerosis, such as ischemic heart diseases. Hyperuricemia consists of over-production and underexcretion, which can be diagnosed by the urate clearance test. Classification is valuable for surveying the underlying diseases of secondary hyperuricemia and treating gouty patients. Underexcretion was observed in 85% of gouty patients with hyperuricemia and even the mean urate clearance in the overproduction type was significantly lower than that of normal controls, suggesting that underexcretion is a fundamental phenomenon in all gouty patients. Treatments of complications as well as those of hyperuricemia with uricosuric agents are required for clinical treatment of gouty patients.
 ...
PMID:[Characteristic features of gouty patients]. 897

Various epidemiological evidences have shown the increased incidence of hyperuricemia in the subjects with hyperlipidemia and/or obesity. Our clinical study indicated the association was more close in hypertriglyceridemia to hyperuricemia than in hypercholesterolemia. Serum uric acid level increased more in Type IIb with elevated lipoprotein lipase (LPL) than those with low or normal LPL. Elevated LPL may be involved in the retarded uric acid clearance due to increased free fatty acids (FFA) in the serum, resulting in the elevation of uric acid and may be linked to the obesity-insulin resistance syndrome. Increased FFA may play an important role on the association of hyperuricemia with hypertriglyceridemia.
 ...
PMID:[Association of hyperuricemia with hyperlipidemia and obesity]. 897 7

Recently atherosclerotic diseases, such as coronary heart disease and cerebrovascular disease have been considered as an important complication of hyperuricemia and gout. However, it is still controversial whether or not hyperuricemia is an independent risk factor of atherosclerotic diseases. On the other hand, several risk factors for coronary heart disease, for example hyperlipidemia and hypertension, are frequently observed in the patients with gout. Atherosclerosis in relation to hyperuricemia was discussed in view of definite and probable risk factors.
 ...
PMID:[Gout and atherosclerosis]. 897 9

There have been described abnormalities in the lipoprotein profile of hyperuricemic patients, it has not been clarified wether these abnormalities are due to the hyperuricemia or to the hyperlipidemia often associated to these patients. Our aim is to study the apolipoprotein profile in hyperuricemic patients without hyperlipidemia compared to a control population. 30 hyperuricemic patients and 26 healthy controls. Measurements were of blood uric acid, total cholesterol, total triglycerides, creatinine, HDL-C, and VLDL cholesterol, triglyceride, Apo B, Apo CII and Apo CIII (1 and 2). Uric acid clearance and fractionated excretion were measured in 24 h. urine samples. No significant differences were found between hyperuricemic and control patients in cholesterol, triglycerides and apo B in VLDL, or LDL and HDL cholesterol. The levels of apo B, Apo AI levels and apo CIII/apo CII were similar in the hyperuricemic and controls. There are two types of hyperuricemic patients, one group associated to hyperlipidemia and would be included in the X Syndrome. The other group not associated to other metabolic abnormalities. Is important to distinguish between these two groups to define the prognosis of a given patient because the greater cardiovascular risk linked hyperuricemic patients could be related to the association to others cardiovascular risks factors.
 ...
PMID:[Lipoprotein profile in patients with isolated hyperuricemia]. 901 94

The relation of hyperuricemia with obesity, arterial hypertension, hyperlipoproteinemia, high intensity of lipid peroxidation, hyperinsulinemia, diabetoid carbohydrate disturbances (abnormal tolerance to carbohydrates and type-II diabetes mellitus) has been investigated in an epidemiological survey of a random population. The study covered 594 citizens of Chuvashia aged 16-65 years (mean age 39.4 +/- 0.5 years). Hyperuricemia is shown to be related with hyperlipidemia, arterial hypertension, obesity, high activity of lipid peroxidation and hyperinsulinemia. It is evident that on the population level hyperuricemia may serve an indicator of hormonal-metabolic athero-, diabetogenic shifts.
 ...
PMID:[Hyperuricemia as a risk factor for noninfectious diseases in the inhabitants of Chuvashia]. 929 74

Sodium-lithium countertransport (SLC) in erythrocytes represents one of the transmembrane sodium transport systems. SLC activity is elevated in arterial hypertension, diabetes mellitus type I (IDDM) complicated with nephropathy, hyperlipidemia, hyperuricemia and pregnancy. Increase of SLC is considered as a genetic marker of primary arterial hypertension. In present paper SLC was assessed in 12 patients with IDDM without nephropathy (group I), 12 patients with IDDM complicated with diabetic nephropathy on hemodialytic treatment (group II), 15 patients treated with haemodialysis due to non-diabetic nephropathy (group III) and 12 healthy subjects (group IV). All groups were matched in respect of age. Serum creatinine concentration and inulin clearance were similar in groups I and IV as well as in groups II and III. SLC was assessed according to method described by Canessa and coworkers (1980). SLC activity in group II (0.60 mmol/l litre of erythrocytes/h; 0.43-0.94; 0.28-1.22) (median, 25%-75%, min.-max.) was significantly higher than in other groups-group I (0.30; 0.20-0.38; 0.12-0.57), group III (0.24; 0.16-0.33; 0.11-0.38) and group IV (0.20; 0.15-0.25; 0.12-0.27). In 3 patients of group I the values were higher than in all examined of groups III and IV and approximated to mean values of group II. The results confirm a significant rise of SLC activity in patients with IDDM complicated with end-stage diabetic nephropathy. SLC activity in end-stage renal disease due to non-diabetic nephropathy does not differ from values in healthy subjects. It seems that elevated SLC activity in IDDM might be a genetic marker foretelling development of nephropathy.
 ...
PMID:[Activity of sodium-lithium cotransport in erythrocytes of patients with diabetes mellitus type I (IDDM) complicated by diabetic nephropathy in the renal failure stage]. 944 Dec 88

We investigated the relationship between the body mass index and the prevalence of coronary risk factors, hypertension, hyperlipidemia, glucose intolerance and hyperuricemia, in middle-aged male workers. We found a positive correlation between the body mass index and the prevalence rate of these coronary risk factors. Mean values for serum total cholesterol, triglyceride, LDL-cholesterol and HbA1c increased with the increase in the body mass index, but decreased in HDL-cholesterol.
 ...
PMID:[The relationship between body mass index and coronary risk factors]. 959 33


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>